No evidence for binding of clozapine, olanzapine and/or haloperidol to selected receptors involved in body weight regulation

Pharmacogenomics Journal

Volumn 7, Issue 4, 2007, Pages 275-281

  Theisen, F M ^a   Haberhausen, M ^a   Firnges, M A ^b   Gregory, P ^b   Reinders, J H ^c   Remschmidt, H ^a   Hebebrand, J ^d   Antel, J ^b  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

^b Solvay Pharmaceuticals GmbH   (Germany)

^c Solvay Pharmaceuticals Inc   (Netherlands)

^d UNIVERSITY OF DUISBURG ESSEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; BOMBESIN RECEPTOR; BOMBESIN RECEPTOR 3; BRADYKININ B2 RECEPTOR; CALCITONIN GENE RELATED PEPTIDE RECEPTOR; CANNABINOID RECEPTOR; CANNABINOID RECEPTOR 1; CHOLECYSTOKININ RECEPTOR; CLOZAPINE; DOPAMINE 1 RECEPTOR; ENDOTHELIN RECEPTOR; GALANIN RECEPTOR 1; HALOPERIDOL; HISTAMINE H1 RECEPTOR; HORMONE RECEPTOR; MELANIN CONCENTRATING HORMONE RECEPTOR; MELANOCORTIN 4 RECEPTOR; MUSCARINIC M1 RECEPTOR; NEUROKININ 1 RECEPTOR; NEUROPEPTIDE Y1 RECEPTOR; NEUROTENSIN RECEPTOR; NEUROTENSIN RECEPTOR 1; NEUROTRANSMITTER; OLANZAPINE; SEROTONIN 2A RECEPTOR; SEROTONIN 2C RECEPTOR; SEROTONIN 6 RECEPTOR; UNCLASSIFIED DRUG; VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTOR 1;

ARTICLE; BINDING AFFINITY; BINDING ASSAY; BINDING SITE; BODY WEIGHT; DRUG RECEPTOR BINDING; PRIORITY JOURNAL; RADIOASSAY; RADIORECEPTOR ASSAY; WEIGHT CONTROL;

ANIMALS; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BODY WEIGHT; CLOZAPINE; HALOPERIDOL; HUMANS; PROTEIN BINDING; RADIOLIGAND ASSAY; RECEPTORS, CELL SURFACE;

EID: 34547646348     PISSN: 1470269X     EISSN: 14731150     Source Type: Journal    
DOI: 10.1038/sj.tpj.6500418     Document Type: Article

References (64)

1. Baptista T. Body weight gain induced by antipsychotic drugs: Mechanisms and management. Acta Psychiatr Scand 1999; 100: 3-16.
2. Allison DB, Mentore JL, Heo M, Chandler LP, Cappelleri JC, Infante MC et at. Antipsychotic-induced weight gain: A comprehensive research synthesis. Am J Psychiatry 1999; 156: 1686-1696.
3. Wirshing DA, Wirshing WC, Kysar L, Berisford MA, Goldstein D, Pashdag J et al. Novel antipsychotics: Comparison of weight gain liabilities. J Clin Psychiatry 1999; 60: 358-363.
4. Theisen FM, Gebhardt S, Haberhausen M, Heinzel-Gutenbrunner M, Wehmeier PM, Krieg JC et al. Clozapine-induced weight gain: A study in monozygotic twins and same-sex sib pairs. Psychiatr Genet 2005, 15: 285-289.
5. Leadbetter R, Shutty M, Pavalonis D, Vieweg V, Higgins P, Downs M. Clozapine-incluced weight gain: Prevalence and clinical relevance. Am J Psychiatry 1992; 149: 68-72.
6. Bromel T, Blum W F, Ziegler A, Schulz E, Bender M, Fleischhaker C et al. Serum leptin levels increase rapidly after initiation of clozapine therapy. Mol Psychiatry 1998; 3: 76-80.
7. Theisen FM, Cichon S, Linden A, Martin M, Remschmidt H, Hebebrand J. Clozapine and weight gain. Am J Psychiatry 2001; 158: 816.
8. Theisen FM, Linden A, Konig IR, Martin M, Remschmidt H, Hebebrand J. Spectrum of binge eating symptomatology in patients treated with clozapine and olanzapine. J Neural Transm 2003; 110: 111-121.
9. Gothelf D, Falk B, Singer P, Kairi M, Phillip M, Zigel L et al. Weight gain associated with increased food intake and low habitual activity levels in male adolescent schizophrenic inpatients treated with olanzapine. Am J Psychiatry 2002; 159: 1055-1057.
10. Graham KA, Perkins DO, Edwards LJ, Barrier Jr RC, Lieberman JA, Harp JB. Effect of olanzapine on body composition and energy expenditure in adults with first-episode psychosis. Am J Psychiatry 2005; 162 118-123.
11. Procyshyn RM, Chau A, Tse G. Clozapine's effects on body weight and resting metabolic rate: A case series. Schizophr Res 2004; 66 159-162.
12. Seeman P. Atypical antipsychotics: Mechanism of action. Can J Psychiatry 2002; 47: 27-38.
13. Basile VS, Masellis M, McIntyre RS, Meltzer HY, Lieberman JA, Kennedy JL. Genetic dissection of atypical antipsychotic-induced weight gain: novel preliminary data on the pharmacogenetic puzzle. J Clin Psychiatry 2001; 62(Suppl 23): 45-66.
14. Basile VS, Masellis M, De-Luca V, Meltzer HY, Kennedy JL. 759C/T genetic variation of 5HT(2C) receptor and clozapine-induced weight gain. Lancet 2002; 360: 1790-1791.
15. Correll CU, Malhotra AK. Pharmacogenetics of antipsychotic-induced weight gain. Psychopharmacology (Berl) 2004; 174: 477-489.
16. Muller DJ, Muglia P, Fortune T, Kennedy JL Pharmacogenetics of antipsychotic-induced weight gain. Pharmacol Res 2004; 49: 309-329.
17. Reynolds GP, Zhang ZJ, Zhang XB. Association of antipsychotic drug-induced weight gain with a 5-HT2C receptor gene polymorphism. Lancet 2002; 359: 2086-2087.
18. Reynolds GP, Zhang ZJ, Zhang XB. Polymorphism of the promoter region of the serotonin 5-HT(2C) receptor gene and clozapine-induced weight gain. Am J Psychiatry 2003; 160: 677-679.
19. Theisen FM, Hinney A, Bromel T, Heinzel-Gutenbrunner M, Martin M, Krieg JC et al. Lack of association between the -759C/T polymorphism of the 5-HT2C receptor gene and clozapine-induced weight gain among German schizophrenic individuals. Psychiatr Genet 2004; 14: 139-142.
20. Tsai SJ, Hong CJ, Yu W, Lin CH. 759C/T genetic variation of 5HT(2C) receptor and clozapine-induced weight gain. Lancet 2002; 360 1790.
21. Miller del D, Ellingrod VL, Holman TL, Buckley PF, Arndt S. Clozapine-induced weight gain associated with the 5HT2C receptor -759C/T polymorphism. Am J Med Genet B Neuropsychiatr Genet 2005; 133 97-100.
22. Templeman LA, Reynolds GP, Arranz B, San L. Polymorphisms of the 5-HT2C receptor and leptin genes are associated with antipsychotic drug-induced weight gain in Caucasian subjects with a first-episode psychosis. Pharmacogenet Genomics 2005; 15: 195-200.
23. Ellingrod VL, Perry PJ, Ringold JC, Lund BC, Bever-Stille K, Fleming F et al. Weight gain associated with the -759C/T polymorphism of the 5HT2C receptor and olanzapine. Am J Med Genet B Neuropsychiatr Genet 2005; 134: 76-78.
24. Kraus T, Haack M, Schuld A, Hinze-Selch D, Kuhn M, Uhr M et al. Body weight and leptin plasma levels during treatment with antipsychotic drugs. Am J Psychiatry 1999; 156: 312-314.
25. Baptista T, Beaulieu S. Are leptin and cytokines involved in body weight gain during treatment with antipsychotic drugs? Can J Psychiatry 2002; 47: 742-749.
26. Hosojima H, Togo T, Odawara T, Hasegawa K, Miura S, Kato Y et al. Early effects of olanzapine on serum levels of ghrelin, adiponectin and leptin in patients with schizophrenia. J Psychophormacol 2006; 20: 75-79.
27. Albaugh VL, Henry CR, Bello NT, Hajnal A, Lynch SL, Halle B et al. Hormonal and metabolic effects of olanzapine and clozapine related to body weight in rodents. Obes Res 2006; 14: 36-51.
28. Theisen FM, Gebhardt S, Bromel T, Otto B, Heldwein W, Heinzel-Gutenbrunner M et al. A prospective study of serum ghrelin levels in patients treated with clozapine. J Neural Transm 2005; 112: 1411-1416.
29. Hauner H, Rohrig K, Hebebrand J, Skurk T. No evidence for a direct effect of clozapine on fat-cell formation and production of leptin and other fat-cell-derived factors. Mol Psychiatry 2003; 8: 258-259.
30. Pollmacher T, Hinze-Selch D, Mullington J. Effects of clozapine on plasma cytokine and soluble cytokine receptor levels. J Clin Psychopharmacol 1996; 16: 403-409.
31. Beck B. KO's and organisation of peptidergic feeding behavior mechanisms. Neurosci Biobehav Rev 2001; 25: 143-158.
32. Sawada H, Yamaguchi H, Shimbara T, Toshinai K, Mondal MS, Date Y et al. Central effects of calcitonin receptor-stimulating peptide-1 on energy homeostasis in rats. Endocrinology 2006; 147: 2043-2050.
33. Vickers SP, Kennett GA. Cannabinoids and the regulation of ingestive behaviour. Curr Drug Targets 2005; 6: 215-223.
34. Fallo F, Mulatero P, Vettor R, Scarda A, Della Mea P, Morello F et al. Bradykinin B2 receptor gene C-58T polymorphism and insulin resistance. A study on obese patients. Horm Metab Res 2004; 36 243-246.
35. Ewert S, Johansson B, Holm M, Helander HF, Fandriks L. The bradykinin BK2 receptor mediates angiotensin II receptor type 2 stimulated rat duodenal mucosal alkaline secretion. BMC Physiol 2003; 3: 1.
36. Said SA, Ammar el SM, Suddek GM. Effect of bosentan (ETA/ETB receptor antagonist) on metabolic changes during stress and diabetes. Pharmacol Res 2005; 51: 107-115.
37. Grundy D, Al-Chaer ED, Aziz Q, Collins SM, Ke M, Tache Y et al. Fundamentals of neurogastroenterology: Basic science. Gastroenterology 2006; 130: 1391-1411.
38. Ulrich II CD, Holtmann M, Miller LJ. Secretin and vasoactive intestinal peptide receptors: Members of a unique family of G protein-coupled receptors. Gastroenterology 1998; 114. 382-397.
39. Cheng Y, Prusoff WH. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (150) of an enzymatic reaction. Biochem Pharmacol 1973; 22: 3099-3108.
40. http://www.gpcr.org/7tm/htmls/consortium.html.
41. Kathmann M, Schlicker E, Gothert M. Intermediate affinity and potency of clozapine and low affinity of other neuroleptics and of antidepressants at H3 receptors. Psychopharmacology (Berl) 1994; 116: 464-468.
42. Bymaster FP, Calligaro DO, Falcone JF, Marsh RD, Moore NA, Tye NC et al. Radioreceptor binding profile of the atypical antipsychotic olanzapine, Neuropsychopharmacology 1996; 14: 87-96.
43. Bymaster FP, Perry KW, Nelson DL, Wong DT, Rasmussen K, Moore NA et al. Olanzapine: A basic science update. Br J Psychiatry Suppl 1999; 37: 36-40.
44. Bymaster FP, Felder CC, Tzavara E, Nomikos GG, Galligaro DO, Mckinzie DL. Muscarinic mechanisms of antipsychotic atypicality. Prog Neuropsychopharmacol Biol Psychiatry 2003; 27: 1125-1143.
45. Kohen R, Metcalf MA, Khan N, Druck T, Huebner K, Lachowicz JE et al. Cloning, characterization, and chromosomal localization of a human 5-HT6 serotonin receptor. J Neurochem 1996; 66: 47-56.
46. Schoemaker H, Claustre Y, Fage D, Rouquier L, Chergui K, Curet O et al. Neurochemical characteristics of amisulpride, an atypical dopamine D2/D3 receptor antagonist with both presynaptic and limbic selectivity. J Pharmacol Exp Ther 1997; 280: 83-97.
47. Arnt J, Skarsfeldt T. Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence. Neuropsychopharmacology 1998; 18: 63-101.
48. Leysen JE, Janssen PFM, Heylen L, Gommeren W, Van Gompel P, Lesage AS et al. Receptor interactions of new antipsychotics: Relation to pharmacodynamic and clinical effects. Int J Psychiat Clin 1998; 2(Suppl 1): 3-17.
49. Milian MJ, Schreiber R, Dekeyne A, Rivet JM, Bervoets K, Mavridis M et al. S 16924
50. Morisset S, Sahm UG, Traiffort E, Tardivel-Lacombe J, Arrang JM, Schwartz JC. Atypical neuroleptics enhance histamine turnover in brain via 5-hydroxytryptamine2A receptor blockade. J Pharmacol Exp Ther 1999; 288: 590-596.
51. Branchek TA, Blackburn TP. 5-ht6 receptors as emerging targets for drug discovery. Annu Rev Pharmacol Toxicol 2000; 40: 319-334.
52. Remschmidt H, Hennighausen K, Clement HW, Heiser P, Schulz E. Atypical neuroleptics in child and adolescent psychiatry. Eur Child Adolesc Psychiatry 2000; 9(Suppl 1): 19-19.
53. Richelson E, Souder T. Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci 2000; 68: 29-39.
54. Campiani G, Butini S, Gemma S, Nacci V, Fattorusso C, Catalanotti B. Pyrrolo [1,3]benzothiazepine-based atypical antipsychotic agents. Synthesis, structure-activity relationship, molecular modeling, and biological studies. J Med Chem 2002; 45: 344-359.
55. http://www.gpcr-org/7tm/ligand/Seeman/index.html.
56. http://www.gpcr.org/7tm/ligand/Organon/index.html.
57. http://www.emea.eu.int/humandocs/PDFs/EPAR/Zyprexa/H-115-Pl-en.pdf.
58. Silvestre JS, Prous J. Research on adverse drug events. J. Muscarinic M3 receptor binding affinity could predict the risk of antipsychotics to induce type 2 diabetes. Methods Find Exp Clin Pharmacol 2005; 27: 289-304.
59. Kroeze WK, Hufeisen SJ, Popadak BA, Renock SM, Steinberg S, Ernsberger P et al. H1-histamine receptor affinity predict short-term weight gain for typical and atypical antipsychotic drugs. Neuropsycho-pharmacalogy 2003; 28: 519-526.
60. Kalra SP, Dube MG, Pu S, Xu B, Horvath TL, Kalra PS. Interacting appetite-regulating pathways in the hypothalamic regulation of body weight. Endocr Rev 1999; 20: 68-100.
61. Stahl SM. Neuropharmacology of obesity: My receptors made me eat it. J Clin Psychiatry 1998; 59: 447-448.
62. Stahl SM. How to appease the appetite of psychotropic drugs. J Clin Psychiatry 1998; 59: 500-501.
63. Hong CJ, Lin CH, Yu YW, Yang KH, Tsai SJ. Genetic variants of the serotonin system and weight change during clozapine treatment. Pharmocagenetics 2001; 11: 265-268.
64. Buckland PR, Hoogendoom B, Guy CA, Smith SK, Coleman SL, O'Donovan MC. Low gene expression conferred by association of an allele of the 5-HT2C receptor gene with antipsychotic-induced weight gain. Am J Psychiatry 2005; 162: 613-615.